-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eflornithine in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eflornithine in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eflornithine in Glioblastoma Multiforme (GBM) Drug Details: Eflornithine is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vididencel in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vididencel in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vididencel in Ovarian Cancer Drug Details: vididencel is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ilixadencel in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ilixadencel in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ilixadencel in Hepatocellular Carcinoma Drug Details: Ilixadencel is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vididencel in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vididencel in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vididencel in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ilixadencel in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ilixadencel in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ilixadencel in Gastrointestinal Stromal Tumor (GIST) Drug Details: Ilixadencel is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fostamatinib Disodium in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fostamatinib Disodium in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fostamatinib Disodium in Hidradenitis Suppurativa Drug Details: Fostamatinib disodium (Tavalisse, Tavlesse)...
-
Product Insights
Colon Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Colon Carcinoma - Drugs In Development, 2023’, provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor Of The Gastrointestinal Tract - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor Of The Gastrointestinal Tract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Mesenchymal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...